# Ona Therapeutics

> Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.

## Why it is interesting

Treatment-resistant cancers evade existing therapies. Ona develops first-in-class antibody-drug conjugates (ADCs) — targeted payloads designed to kill cancer cells that current drugs can't reach. - ADCs are one of oncology's hottest modalities. - Treatment resistance is a major unmet need. - The reopening exit market improves European biotech funding appetite. Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-06-03

## Key facts

- Disclosed financing: $86.6M (Series B)
- Covered in 1 Venture Capital Tracker article(s)

## Related articles

- https://venturecapitaltracker.com/2026-ona-therapeutics-86m-series-b-adc

---
Source: https://venturecapitaltracker.com/startup/ona-therapeutics